SSH - EVANSVILLE LLC.
1. Target Overview & Investment Thesis
SSH - EVANSVILLE LLC. is a 60-bed under-performing / distressed in VANDERBURGH, IN with $21.8M in net patient revenue and a -30.8% operating margin. The hospital serves a payer mix of 40.4% Medicare, 0.8% Medicaid, and 58.8% commercial.
Thesis: Turnaround. Our ML models identify $1.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -30.8% to -23.4% (+736bps).
| Net Revenue HCRIS | $21.8M |
| Current EBITDA COMPUTED | $-6.7M |
| Operating Margin COMPUTED | -30.8% |
| Occupancy HCRIS | 62.5% |
| Revenue / Bed COMPUTED | $364K |
| Net-to-Gross HCRIS | 17.1% |
| Distress Probability ML | 44.6% |
2. Market Context & Competitive Position
IN has 171 Medicare-certified hospitals with a median operating margin of -1.1%. The target's margin of -30.8% places it below the state median. Among 72 size-comparable peers (30-120 beds), the median margin is 1.4%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (30-120), prioritizing same-state peers. 72 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| SSH - EVANSVILLE LLC. (Target) | IN | 60 | $21.8M | -30.8% |
| FRANCISCAN HEALTH MICHIGAN CIT | IN | 119 | $276.7M | 6.1% |
| MEMORIAL HOSP & HEALTH CARE CT | IN | 96 | $259.1M | 28.7% |
| GOSHEN HOSPITAL | IN | 103 | $248.4M | -22.8% |
| GOOD SAMARITAN HOSPITAL | IN | 99 | $233.1M | -12.9% |
| INDIANA ORTHOPAEDIC HOSPITAL L | IN | 38 | $196.8M | 31.2% |
| ST. VINCENT HEART CENTER | IN | 107 | $195.3M | 32.4% |
| LAPORTE HOSPITAL | IN | 74 | $192.4M | 19.3% |
| SCHNECK MEDICAL CENTER | IN | 60 | $184.2M | -0.8% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.6M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $458K | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $436K | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $432K | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $265K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $14K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-6.7M |
| + RCM Uplift | +$1.6M |
| Pro Forma EBITDA | $-5.1M |
| Current Margin | -30.8% |
| Pro Forma Margin | -23.4% |
| WC Released (1x) | $837K |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-10.3M | $-28.3M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-10.3M | $-34.4M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-9.3M | $-32.5M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-9.3M | $-38.2M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-11.4M | $-32.9M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-11.4M | $-39.9M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 72 hospitals with 30-120 beds
- Same-state prioritization (n=73)
- Comp margins: P25=-11.4% / P50=1.4% / P75=14.7%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.